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increasing time between injections. Untreated schizophrenia was rated as very
poor health-related quality of life with a mean (median) utility of 0.27 (0.20). The
treated health states were rated at much higher utilities and were statistically
significantly different (p0.001) from each other: (1) 2-weekly: mean (median) util-
ity  0.61 (0.65); (2) 4-weekly: mean (median) utility  0.65 (0.70); (3) 3-monthly:
mean (median) utility 0.70 (0.75). CONCLUSIONS: This study has provided robust
data indicating that approximately a 0.05 utility difference exists between treat-
ment options, with the highest utility assigned to 3-monthly injections.
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OBJECTIVES: Depression exerts significant morbidity in homebound elders. While
antidepressant medications are effective, little data exist on non-pharmacological
support programs. Beat the Blues (BTB) is a non-pharmacological intervention de-
signed to teach community dwelling depressed African Americans elders coping
skills. BTB was tested in an 8-month randomized two-group experimental design
(treatment vs. wait list control). This analysis examines relationships between
health utility and baseline characteristics of participants.METHODS: Patientswere
enrolled in 2009 and 2010 and eligible if they had depressive symptoms (i.e., PHQ-9
score 5), were African American, 55 years, English speaking, and cognitively
intact (MMSE 24). Data included demographics, co-morbidities, functionality
(ADL, IADL, and mobility), and health utility which were converted from EQ-5D
scores using US scoring algorithm. Regression analyses were conducted to assess
the relationship between health utility and relevant variables with focus on the
relative impact of depression score, with and without adjusting for the study
variables. RESULTS: In the sample (n86), the average age was 68, most were
female (77%), unmarried (92%), non-working (89%), had an average of 6.5 health
conditions (range 1-15), and taking at least onemedication for depression, anxiety,
sleep, or pain. The mean EQ-5D utility index score was 0.56 (SD 0.2); mean PHQ-9
scorewas 12.6 (moderate depression; SD 4.9). EQ-5D index scoreswere significantly
related to PHQ9 score, gender, diabetes, asthma, stroke,multiple sclerosis,memory
problems (p.05) and highly related to functionality (IADL, mobility), foot prob-
lems, number of comorbidities (p.005). After adjusting for patients’ age, educa-
tion, and gender, EQ-5D utility score was significantly decreased as patients had
mobility difficulty, high PHQ9 score, or more comorbidities. CONCLUSIONS: BTB
serves as a unique sample for examination of contributors to health utility in
depressed homebound African American elders. Mobility, depression severity,
and number of comorbidities were significant predictors of health utility in this
population.
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OBJECTIVES: Compliance to treatment in schizophrenia is important to avoid re-
lapse and hospitalization. There is evidence that satisfaction to treatment is posi-
tively associatedwith adherence.We studied patient and physician preference and
satisfaction for different forms of administration of antipsychotic treatment and
drivers behind. METHODS: A non-interventional study including adult patients
diagnosed with schizophrenia and other schizoaffective disorders using long-term
therapy with either atypical orals, atypical LAI (long acting injectables) or other
typical LAI were included. One face-to-facemeetingwas conductedwere a number
of questionnaires were answered by the patient and the physician, MSQ (Medical
Satisfaction Questionnaire), CGI-Severity, DAI (Drug Attitude Inventory) as well as
current and previous medication, adherence, adverse reactions and other back-
ground variables. The hypothesis was that non-.inferiority in MSQ scale between
Atypical LAIs and Atypical oral treatment exist. Statistical method was analysis of
variance with a 95% confidence interval. RESULTS: A total of 265 patients in Swe-
den, Finland, Norway and Denmark with a stable disease during the last three
months were included. Significant differences were observed between oral treat-
ment and injectables in age and time to diagnosis, and were therefore adjusted for
in our analysis. Non-inferiority could be established in theMSQ (primary objective).
The hypothesis of superiority was confirmed in DAI scale, were both Atypical Oral
and Atypical LAI where significant better (p0.0001 and p0.0003) compared to
Typical LAI. Patient own assessment of adherence showed that patients on LAI
were more adherent than patients on Atypical oral treatment, while no difference
between the two LAI existed. CONCLUSIONS: These results suggest that patient
satisfaction with their drug therapy is not determined by the administration form.
Physicians need to have a good understanding of patients preferences and satis-
faction to therapy when initiating drug therapy.
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OBJECTIVES: To assess family functioning from patients’ and partners’ perspec-
tives to better understand the impact of depression on family functioning; To de-
velop and test patient and partner versions of a new self-reported measure, the
Depression and Family Functioning Scale (DFFS), for use in clinical trials.
METHODS: First, 32 in-depth interviews were conducted separately with adults
withmoderate-to-severeMDDand their respective partners to 1) gather qualitative
data describing the impact of depression on family functioning, and 2) identify
constructs relevant to measuring this impact. Next, based on the interview results
and a targeted literature review conducted to supplement these results, 26 items
were drafted to address each aspect of family functioning likely to be affected by
depression. Questionnaire items were then tested and refined through two itera-
tive sets of cognitive interviews with a total of 15 MDD patients and 15 partners of
MDDpatients to allow for enhanced comprehension of questionnaire items, aswell
as optimization of the recall period and response scales used in the final DFFS.
RESULTS: Depression negatively affects family functioning, most notably through
poorer communication, increased conflicts, decreased family interaction, and de-
creased intimacy. Family functioning constructsmost commonly referenced in the
literature review included communication, satisfaction, and cohesion. Draft DFFS
items generally tested well and only minor modifications were made to the items
after the second set of interviews to further facilitate comprehension and accurate
responses. Both patients and partners found the final 15 DFFS items important and
relevant. CONCLUSIONS: Depression negatively affects family functioning in mul-
tiple ways. The DFFS is a brief scale designed to evaluate depression’s impact on
family functioning in patients with MDD and their partners. The DFFS has the
potential to provide unique and important information facilitating more compre-
hensive evaluation of new treatments in clinical trial settings.
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OBJECTIVES: Caregivers of people with schizophrenia experience economic and
humanistic burden which not only affects their quality of life (QoL) and function-
ing, but also compromises the continuity of care to the patients. The goal is to
provide a comprehensive reviewof studies that have assessed the caregiver burden
and to identify instruments that measure caregiver burden in schizophrenia.
METHODS: A systematic literature review was conducted from January 2000 -
December 2010 using a number of medical databases. Studies assessing care-
giver burden were identified after applying the inclusion/exclusion criteria. In
addition, the review also identified instruments along with their psychometric
evaluation. Clinical and review studies were excluded from the systematic
review. RESULTS: The review yielded 22 studies that focused on psychoeduca-
tional interventions designed for caregivers, predictors, mediators and conse-
quences of caregiver burden, and cultural/ethnic differences in caregiving. The
most important predictors of caregiver burden were contact time with the patient,
cohabitationwith the patient, and coping styles of the caregiver. The consequences
of caregiver burdenweremostly psychosocial in nature. The review also yielded 13
instruments (1 generic, 12 condition-specific). The most common domains in-
cluded impact on daily life/household tasks, social life, psychological well-being,
economic burden, time constraints imposed and relationship with healthcare pro-
fessionals. A review of the psychometric properties of these instruments indicated
good reliability (Cronbach’s alpha 0.6 – 0.94). However, responsiveness of the in-
struments was not discussed. CONCLUSIONS: Caregivers play a crucial role in the
management of schizophrenia and with the increasing recognition of caregiver
burden, it is important for healthcare professionals to consider the health and
well-being of caregivers. Understanding the nature and extent of caregiver burden
will facilitate the development of appropriate interventions that can help improve
caregivers’ quality of life (QoL) and functioning.
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OBJECTIVES: To compare quality of life, work productivity loss, and resource use
between respondents diagnosed or not diagnosed with depression and/or experi-
encing sleep difficulties.METHODS:Datawere analyzed fromKantar Health’s 2010
US National Health andWellness Survey, a nationwide survey of adults (18 years
old). Outcome variables were components of the SF-12v2 HRQoL instrument: men-
tal and physical component summary scores (MCS and PCS) and SF6D health util-
ities (measuring health status).Work productivity loss (employed individuals only)
and activity impairment were assessed using the Work Productivity and Activity
Impairment questionnaire. Resource use was measured by the number of tradi-
tional health care provider visits, ER visits and hospitalizations. Linear regressions
and negative binomial regressions, controlling for patient demographics and co-
morbidities, were applied as appropriate. RESULTS: A total of 75,000 respondents
completed the survey, including those diagnosed with depression and experienc-
ing sleep difficulties (n  10,119), depressed without sleep difficulties (n  1,717),
not depressed with sleep difficulties (n  33,341), and not depressed with no sleep
difficulties (n  29,823). Compared with the other groups, those with both depres-
sion and sleep difficulties had poorer PCS, MCS and health utility scores; greater
lost work productivity and activity impairment; and significantly more traditional
healthcare provider visits, ER visits and hospitalizations (all p-values0.05). De-
A195V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
pression with versus without sleep difficulties was associated with lower utility
scores (b-0.04, p0.001), greater work impairment (rate ratio1.4, p0.001), activ-
ity impairment (rate ratio1.30, p0.001), andmore healthcare provider visits (rate
ratio1.31, p0.001). CONCLUSIONS: Sleep difficulties, when combined with de-
pression, are associated with lower quality of life and greater work productivity
loss and health resource use than either sleep difficulties or depression alone, or
neither. Greater attention to sleep problems in depression may lead to better
outcomes.
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OBJECTIVES: Comorbidity risk adjustment methods are increasingly used to re-
duce potential confounding in epidemiological research.We sought to compare the
performances of four comorbidity measures in predicting physical and mental
health among patients with dementia. METHODS: Nationally representative data
from the 2000-2003 Medical Expenditure Panel Survey (MEPS) were used. The Elix-
hauser and the Charlson/D’Hoore, methods were based on the International Clas-
sification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) codes whereas
the Chronic Disease Score (CDS)-1 and the CDS-2 were based on prescription med-
ications. The performances were compared using the R2 obtained from linear re-
gression models. The outcomes of interest were scores on the Medical Outcomes
Short Form-12 (SF-12) Physical Component Scale (PCS) and Mental Component
Scale (MCS). RESULTS: In linear regression models controlling for age and gender
the CDS-2 performed the best (R2 0.242 for PCS, R2 0.157 forMCS) followed by the
Elixhauser (R20.238 for PCS; R20.107 for MCS), the Charlson/D’Hoore (R20.160
for PCS; R20.038 for MCS)and the CDS-1 (R20.154 for PCS; R20.025 for MCS).
Combining the ICD-9-CM based (Elixhauser) measure with the medication based
(CDS-II) measure improved the R2 for both PCS (R2 0.357) and MCS (R20.250).
CONCLUSIONS:We found that CDS-II comorbidity measurement method outper-
forms Elixhauser, Charlson/D’Hoore and CDS-I methods in predicting physical and
mental health in dementia patients studied. Best performance, howver, was ob-
served in themodel that combined diagnoses based (Elixhauser) measure with the
medication based (CDS-II) measure.
PMH57
ASSOCIATION BETWEEN WORK PRODUCTIVITY AND SEVERITY OF
DEPRESSION AMONG FULL-TIME EMPLOYEES AS MEASURED BY THE WPAI &
HPQ
Jain G1, Roy A2, Harikrishnan V2, Yu S2, Dabbous OH2
1Xcenda, LLC., Palm Harbor, FL, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL,
USA
OBJECTIVES: This study examined the burden of depression on employees using
measures ofwork productivity.METHODS: Individuals (18 years of age) employed
full-time with diagnosed depression completed a Web-based computer-generated
25-minute survey in February 2010 (study population identified by Harris Interac-
tive™). The survey used the Patient Health Questionnaire (PHQ-9) to assess depres-
sive symptoms, and the Health and Work Performance Questionnaire (HPQ) and
Work Productivity and Activity Impairment (WPAI) questionnaire to assess absen-
teeism and presenteeism. Higher scores represent more work missed on the HPQ
(hours monthly) and WPAI (% time weekly) absenteeism scales. Higher scores on
the HPQ presenteeism scale (measure of actual performance to possible perfor-
mance, 0-100 scale), and lower scores on the WPAI presenteeism scale (% impair-
ment past 7 days), represent better performance. Work productivity was assessed
by depression severity using a trend test based on an analysis of covariance with
age, gender and PHQ-9 score as independent variables. RESULTS: A total of 1051
full-time employees were evaluated (58% female, mean age 47 yrs). PHQ-9 scores
indicated 423 (40.25%) employees with no depression symptoms, 319 (30.35%) with
mild, 166 (15.79%)withmoderate, 82 (7.80%)withmoderately severe, and 61 (5.80%)
with severe depression. All levels of depression were associated with decreased
work productivity. Both the HPQ (presenteeism [81.04, 73.54, 68.61, 66.10, 61.48, no
depression, mild, moderate, moderately severe, and severe depression groups, re-
spectively], p0.0001) andWPAI (absenteeism [0.92, 3.04, 4.55, 7.43, 14.00] and pre-
senteeism [10.67, 26.17, 38.81, 44.68, 54.31], p0.0001) showed progressive worsen-
ing of work productivity with increasing severity of depression. Pearson’s
coefficient of correlation for WPAI with PHQ-9 was 0.3158 for absenteeism and
0.6055 for presenteeism (p0.0001). CONCLUSIONS: Depression has a significant
impact on work productivity asmeasured by theWPAI and HPQ. Presenteeism and
absenteeism worsened with increasing depression severity, and decreased overall
productivity was seen at all levels of depression severity.
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DECREASES DRUG USE AND INCREASES 12 STEP MEETING ATTENDANCE: ONE
YEAR RESULTS OF A RANDOMIZED CLINICAL TRIAL
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OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is clinically
effective for opioid dependence (OD). Ancillary treatment services, however, may
be needed tomaximize treatment efficacy. The purpose of the present studywas to
investigate the one year effect of a disease management program on treatment
outcomes among a national sample of OD patients.METHODS: Opioid dependent
patients new to B-MAT (N1.426) were randomized to receive either B-MAT plus a
patient support program (intervention group, n  987) or B-MAT alone (standard
care group, n  439). The intervention was a confidential, outbound, telephonic
support program designed to provide new B-MAT patients encouragement and
help them resolve problems inherent to early B-MAT treatment. Once enrolled in
the study, all patients completed the Addiction Severity Index (ASI) and Treatment
Services Review (TSR) at various time points over one year. The ASI is a semi
structured interview designed to measure problem severity in seven functional
areas known to be affected by alcohol and drug dependence. The TSR assess utili-
zation of a variety of health, social, legal, employment, and family support services.
RESULTS: Logistic regression analyses controlling for baseline problem severity
and demographics revealed that intervention group subjectswere significantly less
likely to abuse opioids at month 12 (p  .05; exp ()  1.50), and were significantly
more likely to attend 12 step/self-help groupmeetings for substance abuse (p .05;
exp ()  0.71) compared to the standard care group. CONCLUSIONS: Randomiza-
tion to the diseasemanagement program resulted in a decrease in the reported use
of opioids and an increase in self-help group counseling attendance. Supplement-
ing B-MAT with a structured disease management program seems to be an effec-
tive way to improve patient outcomes. Current results replicate, and extend to
B-MAT, findings from other studies of the effect of telephonic intervention pro-
grams on patient outcomes.
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OBJECTIVES: Opioid dependence (OD) results from the continued abuse of opioids,
which includes prescribed medication for pain (i.e., hyrodcodiene, oxycontin) and
“street” opioids including heroin and methadone. Although patients receive the
same OD diagnosis regardless of their opioid of abuse, prescription and “street”
users represent two distinct patient populations, each with their own unique co-
morbidities and psychosocial profiles. The purpose of this study was to compare
the effectiveness of a new diseasemanagement program (DMP) among the various
types of OD patients. METHODS: A national sample of OD patients new to bu-
prenorphine-medication assisted treatment (B-MAT) were enrolled in the study.
The DMP was a confidential, outbound, telephonic support program designed to
provide new B-MAT patients encouragement and help them resolve problems in-
herent to early B-MAT treatment. All patients completed the Addiction Severity
Index at various time points over the course of the year. Patients were classified
into prescription users (n  303) and street users (heroin or methadone; n  103)
based on their reported opioid of abuse. RESULTS: Street users had significantly
higher baseline legal composite scores (0.13 vs. 0.05; p  0.001), while prescription
users had significantly higher baseline medical (0.31 vs. 0.18; p  0.001) and drug
(0.27 vs. 0.25; p 0.05) composite scores. Within-subjects tests revealed significant
decreases on all three composite scores by month twelve. Additionally, group dif-
ferences on the three composite scores were ameliorated by month twelve (p’s 
.10). CONCLUSIONS: OD patients have a diverse range of medical, social, and sub-
stance abuse histories,making the design of anyDMP for this population especially
complicated. Although patients in this study evidenced two conflicting problem
sets, results showed that the DMP worked equally in ameliorating the challenges
faced by each group, indicating good generalizability of this particular DMP.
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OBJECTIVES:WAVE-bd (WideAmbispectiVE study of the clinicalmanagement and
burden of bipolar disorder [BD]) is ongoing to address limitations of longitudinal BD
studies to-date, few of which investigate caregiver burden. Objectives are to pro-
vide reliable, real-world data, including assessment of burden among caregivers
(usually unpaid relatives or friends), an important consideration in BD patient
management.METHODS:Multinational, multicentre, non-interventional, longitu-
dinal study of patients diagnosed with BD with1 mood event in the preceding 12
months (retrospective data collection from index mood event to enrollment, fol-
lowed by a minimum 9months’ prospective follow-up). Patient selection provided
a representative sample of BD populations in daily practice. Caregiver burden was
assessed using the BurdenAssessment Scale (BAS), where scores range 19–76, with
higher scores indicating greater burden. Assessment was carried out once during
any part of the prospective follow-up for one caregiver only per patient. RESULTS:
To-date, 583/2880 patients (BD-I: 21.8%; BD-II: 16.8%) have attended their baseline
appointment with their primary caregiver (caregiver mean age 50.2 years; 57%
female). The majority of caregivers were patients’ partners or parents (44.1% and
33.5%, respectively), with 10 years of education. The professional status of care-
givers was: employed (47.4%), retired (22.7%), homemaker (16.6%), unemployed
(5.8%) and other (7.4%). BAS scores were collected from 574 caregivers, and total
caregiver burden was 47.6  13.7 (n424) for BD-I and 42.4  12.6 (n150) for BD-II
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